Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus

被引：0

作者：

Lesley J. Scott

Celeste B. Burness

Paul L. McCormack

机构：

[1] Adis,

来源：

BioDrugs | 2012年 / 26卷

关键词：

Systemic Lupus Erythematosus; Placebo Recipient; Infusion Reaction; Physical Component Summary Score; Belimumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Belimumab (Benlysta ®), a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.

引用

页码：195 / 199

页数：4

共 50 条

[21] Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?
Rua-Figueroa, Inigo
Altabas-Gonzalez, Irene
Mourino, Coral
Roberts, Karen
Hernandez-Martin, Andrea
Casafont-Sole, Ivette
Font-Urgelles, Judit
Roman-Ivorra, Jose A.
Navarro, Marta de la Rubia
Galindo-Izquierdo, Maria
Salman-Monte, Tarek C.
Narvaez, Javier
Vidal-Montal, Paola
Garcia-Villanueva, Maria Jesus
Garrote-Corral, Sandra
Blazquez-Canamero, Maria Angeles
Fernandez-Cid, Carlos Marras
Piqueras-Garcia, Maria
Martinez-Barrio, Julia
Sanchez-Lucas, Marina
Cortes-Hernandez, Josefina
Penzo, Eleonora
Calvo-Alen, Jaime
de Dios, Juan Ramon
Alvarez-Rodriguez, Belen
Vasques-Rocha, Margarida
Tomero, Eva
Menor-Almagro, Raul
Gandia, Myriam
Gomez-Puerta, Jose A.
Frade-Sosa, Beatriz
Ramos-Giraldez, Consuelo
Trapero-Perez, Carmen
Diez, Elvira
Moriano, Clara
Munoz-Jimenez, Alejandro
Pego-Reigosa, Jose Maria
RHEUMATOLOGY, 2024, : 1220 - 1224
[22] A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus
Petrou, Panagiotis
VALUE IN HEALTH REGIONAL ISSUES, 2022, 27 : 32 - 40
[23] Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus
Ong, Leong Tung
Chee, Nicholas Ming Zher
CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2021, 7 (03) : 272 - 284
[24] Belimumab for systemic lupus erythematosus: a practice-based view
Parodis, I.
Axelsson, M.
Gunnarsson, I.
LUPUS, 2013, 22 (04) : 372 - 380
[25] Adverse Events Associated with Belimumab Therapy in Systemic Lupus Erythematosus
Leong Tung Ong
Nicholas Ming Zher Chee
Current Treatment Options in Rheumatology, 2021, 7 : 272 - 284
[26] Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus
Akbar, Lujayn
Alsagheir, Razan
Al-Mayouf, Sulaiman M.
EUROPEAN JOURNAL OF RHEUMATOLOGY, 2020, 7 (04) : 184 - 189
[27] The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
Wu, Qi
Zhao, Ming-Xue
Huang, Xiao-Shan
Lin, Chang-song
Xu, Qiang
LUPUS, 2024, 33 (06) : 608 - 614
[28] Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report
Danve, Abhijeet
Perry, Lisa
Deodhar, Atul
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (02) : 195 - 197
[29] Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
Guzman, Marla
Hui-Yuen, Joyce S.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 2503 - 2513
[30] Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
Lu, Chaofan
He, Nan
Dou, Lei
Yu, Hongxia
Li, Mengtao
Leng, Xiaomei
Zeng, Xiaofeng
IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (08)

← 1 2 3 4 5 →